Abstract
Coat protein complex I (COP-I) mediates the retrograde transport from the Golgi apparatus to the endoplasmic reticulum (ER). Mutation of the COPA gene, encoding one of the COP-I subunits (α-COP), causes an immune dysregulatory disease known as COPA syndrome. The molecular mechanism by which the impaired retrograde transport results in autoinflammation remains poorly understood. Here we report that STING, an innate immunity protein, is a cargo of the retrograde membrane transport. In the presence of the disease-causative α-COP variants, STING cannot be retrieved back to the ER from the Golgi. The forced Golgi residency of STING results in the cGAS-independent and palmitoylation-dependent activation of the STING downstream signaling pathway. Surf4, a protein that circulates between the ER/ ER-Golgi intermediate compartment/ Golgi, binds STING and α-COP, and mediates the retrograde transport of STING to the ER. The STING/Surf4/α-COP complex is disrupted in the presence of the disease-causative α-COP variant. We also find that the STING ligand cGAMP impairs the formation of the STING/Surf4/α-COP complex. Our results suggest a homeostatic regulation of STING at the resting state by retrograde membrane traffic and provide insights into the pathogenesis of COPA syndrome.
Subject terms: Golgi, Golgi, Pattern recognition receptors
COPA regulates Golgi to ER transport, and mutations lead to autoinflammation and disease through poorly understood mechanisms. Here, the authors show that disease-causing COPA variants prevent STING transport from the Golgi to the ER, leading to cGAS-independent activation of the STING pathway.
Introduction
The COPA syndrome is a recently discovered monogenic disorder of immune dysregulation characterized by high-titer autoantibodies, interstitial lung disease, inflammatory arthritis, and high expression of type I interferon-stimulated genes1,2. The disease is caused by heterozygous mutations of the COPA gene, encoding the α subunit (α-COP) of COP-I that mediates the retrograde transport of proteins from the Golgi to the endoplasmic reticulum (ER)3,4. All of the mutations1 of the disease-causative α-COPs lie in the N-terminal WD40 domain (Supplementary Fig. 1a), which has been implicated in the recognition of cargo proteins5. How the retrograde transport in the COPA syndrome causes the immune dysregulatory disease remains largely unknown.
Vertebrates have evolved biological systems to combat invading pathogens. As the first line of host defense, the innate immune system detects microbial pathogens with pattern recognition receptors (PRRs) that bind unique pathogen-associated molecular patterns (PAMPs)6,7. Activated PRRs initiates intracellular signaling cascades, leading to the transcriptional expression of proinflammatory cytokines, type I interferons, and other antiviral proteins that all coordinate the elimination of pathogens and infected cells. Viral RNA, cytosolic DNA, or the gram-negative bacterial cell-wall component lipopolysaccharide serves as PAMP that activates a distinct signaling pathway, such as RIG-I/MAVS, cGAS/STING, or TLR4/TRIF pathway. MAVS, STING, or TRIF activates the downstream protein kinase TBK1, which then phosphorylates and activates interferon regulatory factor 3 (IRF3), the essential transcription factor that drives type I interferon production8.
STING9 is an ER-localized transmembrane protein. After STING binding to cyclic dinucleotides (CDNs)10 that are generated by cGAMP synthase (cGAS)11, an enzyme that is activated by the presence of cytosolic DNA, STING translocates to the Golgi where STING activates TBK1 at the trans-Golgi network (TGN)12–14. Because α-COP is a component of COP-I that mediates the membrane transport between the Golgi and the ER, we reasoned that the disease-causative α-COP variant (K230N, R233H, E241K, or D243G; the α-COP variant hereafter)1 could influence the STING pathway.
In this work, we show that the disease-causing COPA variants prevent STING transport to the ER, leading to cGAS-independent activation of the STING pathway.
Results
The α-COP variants activate the STING pathway
We performed luciferase assay with HEK293T cells that lack endogenous STING. After co-transfection with α-COP, STING, and a luciferase reporter construct with IRF3 (also known as ISRE or PRD III-I)-responsive promoter elements, the luciferase activity in the total cell lysate was measured. Wild-type α-COP did not activate the IRF3 promoter regardless of the expression of STING, while all the α-COP variants activated the IRF3 promoter in STING-expressing cells (Fig. 1a). The α-COP variants did not activate the IRF3 promoter in cells transfected with MAVS or TRIF (Supplementary Fig. 1b, c).
The effects of the α-COP variants on STING signaling were modest in this transient transfection system, possibly because of STING overexpression10. Therefore, we examined the effects of wild-type or mutant α-COP in cells stably expressing STING in Sting−/− MEFs. The amount of STING in Sting−/− MEFs stably expressing EGFP-STING was ~3-fold higher than that of endogenous STING in WT MEFs (Supplementary Fig. 1d). We then stably expressed wild-type or mutant α-COP in Sting−/− MEFs expressing EGFP-STING. Both wild-type and mutant α-COP localized mainly at the Golgi (Supplementary Fig. 2a–e). Other COP-I subunits (β, β′, δ, and γ) also localized at the Golgi in these cells (Supplementary Fig. 2a–d). We also examined the expression levels of these COP-I subunits by western blot, and found that the stable expression of α-COP did not affect that of other COP-I subunits (Supplementary Fig. 2f, g). We then examined activation of STING pathway in these cells. Phosphorylated TBK1 (p-TBK1), a hallmark of STING activation, emerged only in cells expressing the α-COP variants (Fig. 1b and Supplementary Fig. 18a). Several innate immunity genes, which are reported to be upregulated in MEFs expressing constitutively active STING15, were also upregulated in cells expressing the α-COP variants (Fig. 1c and Supplementary Fig. 3). These results suggested that expression of the α-COP variants could activate the STING pathway. Given that the α-COP variants can be defective in cargo recognition1 (Supplementary Fig. 1a) and that the localization and amount of COP-I subunits including endogenous α-COP were not affected by the expression of the α-COP variants (Supplementary Fig. 2), the α-COP variants would decrease the number of functional COP-I complex. Therefore, the effect of the disease-causative α-COP variants on activation of STING pathway may be dominant negative.
The α-COP variants alter STING localization to the Golgi
We next examined the subcellular localization of STING. In cells expressing wild-type α-COP, EGFP-STING distributed throughout the cytoplasm and co-localized with calreticulin (an ER protein), indicating that STING localized at the ER (Fig. 2a and Supplementary Figs. 4 and 18b). p-TBK1 and phosphorylated STING at Ser365 (p-STING) that is generated by active TBK18,16 were not detected. In contrast, in cells expressing the α-COP variants, EGFP-STING mostly localized at perinuclear compartments that include the Golgi (Fig. 2a and Supplementary Figs. 4–7 and 18b). Thus, the expression of the α-COP variants altered the STING localization. The signals of p-TBK1 and p-STING emerged in these cells (Fig. 2b and Supplementary Figs. 8–10 and 18c), being consistent with the activation of STING (Fig. 1). Immunoelectron microscopy corroborated the Golgi localization of STING in cells expressing the α-COP variant (E241K; Fig. 2c and Supplementary Figs. 18d and 19). Given that COP-I mediates the retrograde transport from the Golgi to the ER4, these results suggested that STING is a cargo of the retrograde transport of COP-I and that STING cannot be retrieved back to the ER in the presence of the disease-causative α-COP variants. The amount of STING that was co-immunoprecipitated with the α-COP variants was smaller than that with wild-type α-COP (Fig. 2d), further supporting this notion.
Surf4 binds STING and α-COP, and is required for STING localization to the ER
α-COP binds C-terminal di-lysine motifs of its cargo proteins, such as KKXX and KXKXX3,17,18. As STING does not possess these motifs at its C-terminus, we reasoned the presence of adapter protein(s) that mediates the interaction of STING and α-COP. We analyzed STING-binding proteins by mass spectrometry and 18 proteins with these motifs were identified (Supplementary Table 1). We knock-downed these proteins individually with siRNAs and examined the effect on the subcellular localization of STING. We found that knockdown of Surf4, not that of the other 17 proteins, altered the localization of STING to the Golgi (Fig. 3a, b and Supplementary Figs. 11 and 12). Knockdown of Surf4 also resulted in the emergence of p-TBK1 in Sting−/− MEFs that were reconstituted of EGFP-STING, but not in Sting−/− MEFs (Fig. 3c). These results suggested that Surf4 is critical to maintain the steady-state localization of STING to the ER.
Surf4, a multi-pass transmembrane protein, cycles among the ER, ERGIC, and the Golgi. Surf4 functions in the anterograde trafficking pathway from the ER19. Surf4 is involved in membrane recruitment of COP-I20, suggesting that Surf4 also functions in the retrograde trafficking pathway. Indeed, we found the interaction between Surf4 and wild-type α-COP by co-immunoprecipitation analysis (Fig. 3d). The mutant Surf4 (K265A/K266A/K267A), in which the C-terminal lysine residues were substituted to alanine, exhibited a reduced binding to α-COP, suggesting that the interaction between Surf4 and COPA is, at least in part, mediated through the C-terminal consecutive lysine residues on Surf4 (Fig. 3d and Supplementary Fig. 18e). We performed the knockdown/rescue experiments with wild-type and the mutant Surf4. The expression of wild-type Surf4, but not the mutant Surf4 (K265A/K266A/K267A), rescued the ER localization of STING (Supplementary Fig. 13c). These results suggested that the interaction of Surf4 with α-COP through the C-terminal KKK motif (Fig. 3d) was essential for the STING retrieval to the ER. The disease-causative α-COP variant (E241K) exhibited a reduced binding to Surf4 (Fig. 3e and Supplementary Fig. 18e). Moreover, knockdown of Surf4 reduced the binding between STING and α-COP (Supplementary Fig. 13d). These results suggested that Surf4 serves as a cargo receptor for STING in the retrograde transport mediated by COP-I.
We examined the subcellular localization of Surf4. Surf4 localized at punctate structures, some of which were positive with α-COP, but not with TGN38 (Supplementary Fig. 14a), suggesting that these puncta represent ERGIC. Surf4 co-localized with ERGIC53 (a protein that circulates among the ER, ERGIC, and the Golgi) at these punctate structures (Supplementary Fig. 14b), supporting that these puncta indeed represent ERGIC. Based on these results, in particular the one that Surf4 co-localized with α-COP in ERGIC, we assume that Surf4 was involved in the retrograde transport of STING from the ERGIC to the ER.
STING activation with the α-COP variants requires the retrograde membrane traffic and palmitoylation of STING, but not cGAS
Activation of the STING signaling pathway with cGAMP requires the ER-to-Golgi traffic of STING and palmitoylation of STING at the Golgi12,13,21. We treated cells expressing the α-COP variants with brefeldin A (BFA), an agent to block the ER-to-Golgi traffic22, or two palmitoylation inhibitors [a pan-palmitoylation inhibitor 2-bromopalmitate (2-BP) and a mouse STING-specific palmitoylation inhibitor C-17823] and found that these treatments suppressed phosphorylation of TBK1 and the expression of Ccl5, Cxcl10, and Apol9b (Fig. 4a, b and Supplementary Fig. 15c). These results suggested that STING activation with the α-COP variants, as with cGAMP, requires the ER-to-Golgi traffic and palmitoylation of STING.
We asked if the activation of STING caused by impaired retrograde transport requires cGAMP. To address this question, we prepared cGAS-knockout MEFs by CRISPR-Cas9 system (Supplementary Fig. 16a). In cGAS-knockout MEFs expressing the α-COP variants, (i) p-TBK1 still emerged (Fig. 4c), (ii) the gene expression of Ccl5, Cxcl10, and Apol9b were induced (Supplementary Fig. 16b), and (iii) STING translocated to perinuclear compartments that include the Golgi (Supplementary Fig. 16c). We depleted Surf4 by siRNA in cGAS-knockout cells and found that STING still translocated to the Golgi (Supplementary Fig. 13a) and that TBK1 was phosphorylated (Supplementary Fig. 13b). These results suggested that the translocation of STING from the ER to the Golgi does not necessarily require cGAMP and that the forced Golgi residency of STING with the impaired retrograde transport would suffice to activate the STING signaling pathway in the absence of cGAMP.
The translocation of STING from the ER to the Golgi in cGAS-knockout MEFs expressing the α-COP variants were suppressed by knockdown of Sar1a/b (Supplementary Fig. 17), which are two small GTPases responsible for the ER exit of STING13. These results led us to propose a model to explain how the membrane traffic axis between the ER and the Golgi is integrated into the STING signaling pathway (Fig. 4d). STING exits the ER without cGAMP by COP-II-mediated anterograde transport (Supplementary Fig. 17). This exit may be with bulk flow as part of the membrane without association with COP-II coat subunits. Once STING reaches the ERGIC (Supplementary Fig. 14), STING is retrieved back to the ER by the COP-I-mediated retrograde transport. In a condition where the retrograde transport is impaired, such as in the presence of the disease-causative α-COP variants (Fig. 2), or where retrograde pathway is saturated because of STING overexpression9,10, STING is forced to accumulate at the Golgi. STING is then subjected to palmitoylation and activates TBK1 at TGN12 (Supplementary Fig. 8).
Intriguingly, STING with DMXAA (a mouse STING agonist) or with cGAMP exhibited a reduced binding to α-COP and Surf4 (Fig. 4e, f). Therefore, the translocation of STING from the ER and activation of the STING signaling pathway with cGAMP may be partly due to the reduced ability of the STING/ligand complex to be packaged into COP-I transport vesicles. Mutations in STING are found in patients with an autoinflammatory disease called STING-associated vasculopathy with onset in infancy (SAVI) and these mutations appear to make STING constitutively active24–26. The SAVI variants exit the ER without cGAMP13 and require the ER-to-Golgi traffic and palmitoylation for their activity12,13. We found that all the six SAVI variants exhibited a reduced binding to Surf4 (Fig. 4g). The reduced binding may result in the impaired retrograde transport of STING to the ER, which would partly explain the aberrant localization of the SAVI variants to the Golgi without cGAMP.
Discussion
In this study, we demonstrate the homeostatic regulation of STING at the resting state by the retrograde membrane traffic. Intriguingly, this finding is corroborated in a recently described mouse model of COPA syndrome (CopaE241K/+ mice)27: CopaE241K/+ mice exhibit spontaneous activation of STING with upregulation of type I interferon signaling and systemic inflammation, all of which is abrogated in STING-deficient animals28. However, given the multiple cargo proteins transported by COP-I vesicles, other effects of α-COP loss-of-function may also contribute to the COPA syndrome-specific symptoms, which are not manifested in SAVI in which STING is constitutively active because of the STING mutations. Nonetheless, our results that the inflammatory response in the presence of the α-COP variants can be effectively suppressed by STING palmitoylation inhibitors may provide a treatment approach for COPA syndrome patients.
Methods
Antibodies
Antibodies used in this study were as follows: mouse anti-GFP (JL-8, dilution 1:1000; Clontech); rabbit anti-β-COP (PA1-061, dilution 1:2000 for western blot and immunofluorescence), rabbit anti-mCherry for detecting mScarlet-I (PA5-34974, dilution 1:1000 for western blot), and Alexa 488-, 594-, or 647-conjugated secondary antibodies (A21202, A21203, A21206, A21207, A31573, A11016, A21448, dilution 1:2000; Thermo Fisher Scientific); rabbit anti-TBK1 (ab40676, dilution 1:1000; Abcam); rabbit anti-phospho-TBK1 (D52C2, dilution 1:1000 for western blot, dilution 1:100 for immunofluorescence), rabbit anti-cGAS (D3O8O, dilution 1:1000), and rabbit anti-phospho-STING (D1C4T, dilution 1:400; Cell signaling); mouse anti-calreticulin (612136, dilution 1:1000), and mouse anti-GM130 (610823, dilution 1:1000; BD Biosciences); rabbit anti-α-COP (HPA028024, dilution 1:1000 for western blot), mouse anti-α-tubulin (DM1A, dilution 1:5000) and mouse anti-FLAG M2 antibody (Sigma); Goat Anti-Rabbit IgG(H + L) Mouse/Human ads-HRP (4050-05, dilution 1:10,000) and Goat Anti-Mouse IgG(H + L) Human ads-HRP (1031-05, dilution 1:10,000; Southern Biotech); sheep anti-TGN38 (AHR499G, dilution 1:500) (Serotec); rabbit anti-STING antibody (19851-1-AP, dilution 1:1000 for western blot), rabbit anti-γ-COP (12393-I-AP, dilution 1:1000 for western blot, dilution 1:200 for immunofluorescence), and rabbit anti-ERGIC53 (13364-1-AP, dilution 1:200 for immunofluorescence; Proteintech); mouse anti-HA (4B2, dilution 1:1000 for western blot and immunofluorescence) and mouse anti-FLAG (1E6, dilution 1:1000 for western blot and immunofluorescence, dilution 1:50 for immunoelectron microscopy; Wako); rabbit anti-β′-COP (A304-523A-T, dilution 1:1000 for western blot, dilution 1:200 for immunofluorescence; Bethyl Laboratories); mouse anti-δ-COP (GTX630562, dilution 1:1000 for western blot, dilution 1:200 for immunofluorescence; GeneTex); 12 nm colloidal gold particle-conjugated donkey anti-rabbit antibody (711-205-152, dilution 1:20) and 6 nm colloidal gold particle-conjugated donkey anti-mouse IgG (715-195-150, dilution 1:20; Jackson ImmunoResearch laboratories). For the immunoprecipitation of FLAG-tagged protein, anti-FLAG M2 Affinity Gel (A2220, Sigma) was used. For the immunoprecipitation of GFP-tagged protein, anti-GFP nanobody was used. pGEX6P1-GFP-Nanobody was a gift from Kazuhisa Nakayama (Addgene plasmid # 61838).
Reagents
The following reagents were purchased from the manufacturers as noted: BFA (Sigma); 2-BP (Wako). ISD (90-mer), used as dsDNA in this study, was prepared as follows: equimolar amounts of oligonucleotides (sense: 5′-TACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACATACAGATCTACTAGTGATCTATGACTGATCTGTACATGATCTACA-3′, antisense: 5′-TGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGTATGTAGATCATGTACAGATCAGTCATAGATCACTAGTAGATCTGTA-3′) were annealed in PBS at 70 °C for 30 min before cooling to room temperature. C-178 was provided by Carna Biosciences, Inc.
Cell culture
HEK293T cells were purchased from the American Type Culture Collection (ATCC). MEFs were obtained from embryos of WT or Sting−/− mice at E13.5 and immortalized with SV40 Large T antigen. HEK293T and MEFs were cultured in DMEM supplemented with 10% fetal bovine serum/penicillin/streptomycin/glutamine in a 5% CO2 incubator.
MEFs that stably express EGFP-mouse STING or mouse α-COP variants were established using retrovirus. Plat-E cells were transfected with pMX-IP-EGFP-STING or pMX-IB-α-COP-FLAG and the medium that contains the retrovirus was collected. MEFs were incubated with the medium and then selected with puromycin (2 µg/mL) or blasticidin (5 µg/mL) for several days.
PCR cloning
Mouse STING was amplified by PCR with complementary DNA (cDNA) derived from ICR mouse liver. The product encoding mouse STING was introduced into pMXs-IPuro–GFP, to generate N-terminal GFP-tagged construct. Mouse α-COP and mouse Surf4 was amplified by polymerase chain reaction (PCR) with cDNA derived from MEFs. The product encoding α-COP was introduced into pMXs-IBla-FLAG, to generate C-terminal FLAG-tagged construct. The product encoding Surf4 was introduced into pMXs-IHyg-HA, to generate N-terminal HA-tagged construct. α-COP variants and Surf4 mutant were generated by site-directed mutagenesis.
Luciferase assay
HEK293T cells seeded on 24-well plates were transiently transfected with luciferase reporter plasmid (100 ng), pRL-TK (10 ng) as internal control, STING-expression plasmid in pBabe vector (200 ng), and α-COP-expression plasmid in pMX vector (200 ng) Twenty-four hours after the transfection, the luciferase activity in the total cell lysate was measured.
qRT-PCR
Total RNA was extracted from cells using Isogen II (Nippongene), and reverse-transcribed using ReverTraAce qPCR RT Master Mix with gDNA Remover (TOYOBO). Quantitative real-time PCR (qRT-PCR) was performed using KOD SYBR qPCR (TOYOBO) and LightCycler 96 (Roche). The sequences of the primers were provided in Supplementary Table 2. Target gene expression was normalized on the basis of GAPDH content.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA) in PBS at room temperature for 15 min, permeabilized with 0.1% Triton X-100 in PBS at room temperature for 5 min, and quenched with 50 mM NH4Cl in PBS at room temperature for 10 min. After blocking with 3% BSA in PBS, cells were incubated with primary antibodies, then with secondary antibodies conjugated with Alexa fluorophore.
Confocal microscopy
Confocal microscopy was performed using a LSM880 with Airyscan (Zeiss) with a 63 × 1.4 Plan-Apochromat oil immersion lens or 100 × 1.46 alpha-Plan-Apochromat oil immersion lens. Images were analyzed with Zeiss ZEN 2.3 SP1 FP3 (black, 64 bit) (ver. 14.0.21.201) and Fiji (ver. 2.1.0/1.53c).
Immunoprecipitation
Cells were lysed with IP buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, 5 mM EDTA, 1% CHAPS, protease inhibitors (Protease Inhibitor Cocktail for Use with Mammalian Cell and Tissue Extracts, 25955-11, nacalai tesque), and phosphatase inhibitors (8 mM NaF, 12 mM beta-glycerophosphate, 1 mM Na3VO4, 1.2 mM Na2MoO4, 5 µM cantharidin, and 2 mM imidazole). The lysates were centrifugated at 20,000 × g for 10 min at 4 °C, the resultant supernatants were incubated for overnight at 4 °C with anti-FLAG M2 Affinity Gel or anti-GFP nanobody beads29 for 1 h. The beads were washed four times with immunoprecipitation wash buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, 0.7% CHAPS), and eluted with elution buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 200 µg/mL FLAG peptide).
Immunoelectron microscopy
Cells were fixed with 4% PFA (1.04005.1000, MERCK), 4% sucrose, and 0.1 M phosphate buffer (pH 7.2) for 10 min at room temperature and then 30 min at 4 °C. After rinsing with 7.5% sucrose and 0.1 M phosphate buffer (pH 7.4), they were scraped and embedded in 10% gelatin (G2500, Sigma) and 0.1 M phosphate buffer (pH 7.4). The cell blocks were cut into small pieces (~1 mm cube), which were infused overnight with 20% polyvinylpyrrolidone (PVP10, Sigma-Aldrich), 1.84 M sucrose, 10 mM Na2CO3, and 0.08 M phosphate buffer (pH 7.4) followed by rapid freezing in liquid nitrogen30. Ultrathin cryosections were prepared using an ultramicrotome (EM UC7, Leica) equipped with a cryochamber (EM FC7, Leica). They were incubated with 1% BSA and PBS for 20 min at room temperature, and then with rabbit antibody against GFP (ab6556, dilution 1:100; Abcam) and mouse antibody against FLAG (1E6, dilution 1:50; Wako) for 24 h at 4 °C. After incubation with 12 nm colloidal gold particle-conjugated donkey anti-rabbit (711-205-152, dilution 1:20; Jackson ImmunoResearch) and 6 nm colloidal gold particle-conjugated donkey anti-mouse IgG (715-195-150, dilution 1:20; Jackson ImmunoResearch) for 1 h at room temperature, they were fixed with 2% glutaraldehyde (G017/1, TAAB) and PBS for 5 min. They were stained with 2% uranyl acetate for 5 min and embedded in 0.17% uranyl acetate and 0.33% polyvinyl alcohol (P8136, Sigma-Aldrich). After drying up, sections were observed using an electron microscope (JEM1200EX, JEOL).
western blot
Proteins were separated in polyacrylamide gel and then transferred to polyvinylidene difluoride membranes (Millipore). These membranes were incubated with primary antibodies, followed by secondary antibodies conjugated to peroxidase. The proteins were visualized by enhanced chemiluminescence using a LAS-4000 (GE Healthcare) or Fusion SOLO.7S.EDGE (Vilber-Lourmat).
Mass spectrometry
Cells were lysed with IP buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, protease inhibitors, and phosphatase inhibitors). The lysates were centrifugated at 20,000 × g for 10 min at 4 °C, the resultant supernatants were incubated for overnight at 4 °C with anti-FLAG M2 Affinity Gel. The beads were washed four times with immunoprecipitation wash buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, and 1% Triton X-100), and eluted with elution buffer (50 mM HEPES-NaOH (pH 7.2), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 500 µg/mL FLAG peptide. Eluted proteins were applied to SDS-PAGE, and the electrophoresis was stopped when the samples were moved to the top of the separation gel. The gel was stained with CBB and the protein bands at the top of separation gel were excised. The proteins were reduced and S-carboxylmethylated, followed by a tryptic digestion in gel (TPCK treated trypsin, Worthington Biochemical Corporation). The digests were separated with a reversed phase nano-spray column (NTCC-360/75-3-105, NIKKYO technos) and then applied to Q Exactiv Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific). MS and MS/MS data were obtained with TOP10 method. The MS/MS data was searched against NCBI nr database using MASCOT program 2.6 (Matrix Science) and the MS data was quantified using Proteome Discoverer 2.2 (Thermo Scientific).
RNA interference
siRNA specific to Ablim1 (M-059643-01), Clptm1l (M-062856-00), Ddost (M-064791-00), H13 (M-059025-01), Hsd17b12 (M-060708-01), Lpcat1 (M-059984-01), Mars (M-066281-00), Myl12a (M-046975-01), Ncl (M-059054-01), Ncln (M-052038-01), Psmd11 (M-057766-01), Hacd3 (M-065373-01), Slc25a4 (M-061103-01), Slc25a5 (M-042392-01), Smpd4 (M-042323-01), Stt3b (M-062290-01), Surf4 (M-062783-00), and Tmem43 (M-046911-01) were purchased from Dharmacon. siRNA specific to Surf4 (Surf4 Stealth Select RNAi) purchased from Thermo Fisher Scientific. Negative control siRNA was purchased from Dharmacon and Thermo Fisher Scientific. A total of 20 nM siRNA was introduced to cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instruction. After 6 h, the medium was replaced by DMEM with 10% heat-inactivated FBS and cells were further incubated for 44 or 68 h for subsequent experiments.
Statistics and reproducibility
Error bars displayed throughout this study represent s.e.m. unless otherwise indicated, and were calculated from triplicate or quadruplicate samples. Statistical significance was determined with R (ver. 4.0.2) by one-way ANOVA followed by Tukey–Kramer post hoc test.; *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant (P > 0.05). Data shown are representative of three independent experiments (Figs. 1b; 2a–d; 3b–f; and 4a–c, e–g; Supplementary Figs. 1d, e; 2a–g; 4–7; 8a, b; 9–11; 12b; 13a–d; 14a, b; 15a, b, d; 16a, c; 17; and 19) and each yielding similar results.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
This work was supported by JSPS KAKENHI Grant Numbers JP19H00974 (T.T.), JP15H05903 (T.T.), JP17H06164 (H.A.), JP17H06418 (H.A.), JP20H05307 (K.M.), JP20H03202 (K.M.), and JP17K15445 (K.M.); AMED-PRIME (17939604) (T.T.); Takeda Science Foundation (to S.W. and to K.M.), MSD Life Science Foundation (Public Interest Incorporated Foundation) (K.M.), Daiichi Sankyo Foundation of Life Science (K.M.), the Research Foundation For Pharmaceutical Sciences (K.M.), Young Investigator Grant (Graduate School of Life Sciences, Tohoku University) (K.M.), Foundation for Promotion of Cancer Research in Japan (K.M.), the Cell Science Research Foundation (K.M.), the Pharmacological Research Foundation Tokyo (K.M.), the Japan Foundation for Applied Enzymology (K.M.), and Tokyo Biochemical Research Foundation (K.M.), Center of Innovation program from Japan (K.M.), Grant for Basic Science Research Projects from the Sumitomo Foundation (K.M.), Koyanagi-Foundation (K.M.), and the Nakatomi Foundation (K.M.). We thank Atsuko Yabashi for her technical support in the immuno-EM.
Source data
Author contributions
K.M. designed and performed the experiments, analyzed the data, interpreted the results, and wrote the paper; E.O. designed and performed experiments, analyzed data, and interpreted results; R.U. performed the experiments for identification of STING binding proteins; Y.K. performed the experiments with cGAS KO cells; F.K. constructed the plasmids; T.U. and S.W. performed the experiments with electron microscopy; T.S. and N.D. performed the proteomics analysis; H.A. designed the experiments, interpreted the results; A.K.S. discussed the results; T.T. designed the experiments, interpreted the results, and wrote the paper.
Data availability
The authors declare that the data supporting the findings of this study are available within the paper, Supplementary Information or from the corresponding author upon request. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Peer review information Nature Communications thanks Elizabeth Miller and other, anonymous, reviewers for their contributions to the peer review of this work. Peer review reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information is available for this paper at 10.1038/s41467-020-20234-9.
References
- 1.Watkin LB, et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat. Genet. 2015;47:654–660. doi: 10.1038/ng.3279. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Volpi S, et al. Type I interferon pathway activation in COPA syndrome. Clin. Immunol. 2018;187:33–36. doi: 10.1016/j.clim.2017.10.001. [DOI] [PubMed] [Google Scholar]
- 3.Letourneur F, et al. Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic reticulum. Cell. 1994;79:1199–1207. doi: 10.1016/0092-8674(94)90011-6. [DOI] [PubMed] [Google Scholar]
- 4.Scales SJ, Pepperkok R, Kreis TE. Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI. Cell. 1997;90:1137–1148. doi: 10.1016/S0092-8674(00)80379-7. [DOI] [PubMed] [Google Scholar]
- 5.Eugster A, Frigerio G, Dale M, Duden R. COP I domains required for coatomer integrity, and novel interactions with ARF and ARF-GAP. EMBO J. 2000;19:3905–3917. doi: 10.1093/emboj/19.15.3905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 2009;227:221–233. doi: 10.1111/j.1600-065X.2008.00731.x. [DOI] [PubMed] [Google Scholar]
- 7.Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820. doi: 10.1016/j.cell.2010.01.022. [DOI] [PubMed] [Google Scholar]
- 8.Liu S, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science. 2015;347:aaa2630. doi: 10.1126/science.aaa2630. [DOI] [PubMed] [Google Scholar]
- 9.Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674–678. doi: 10.1038/nature07317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Burdette DL, et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478:515–518. doi: 10.1038/nature10429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786–791. doi: 10.1126/science.1232458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Mukai K, et al. Activation of STING requires palmitoylation at the Golgi. Nat. Commun. 2016;7:11932. doi: 10.1038/ncomms11932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ogawa E, Mukai K, Saito K, Arai H, Taguchi T. The binding of TBK1 to STING requires exocytic membrane traffic from the ER. Biochem. Biophys. Res. Commun. 2018;503:138–145. doi: 10.1016/j.bbrc.2018.05.199. [DOI] [PubMed] [Google Scholar]
- 14.Taguchi T, Mukai K. Innate immunity signalling and membrane trafficking. Curr. Opin. Cell Biol. 2019;59:1–7. doi: 10.1016/j.ceb.2019.02.002. [DOI] [PubMed] [Google Scholar]
- 15.Konno H, et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. Cell Rep. 2018;23:1112–1123. doi: 10.1016/j.celrep.2018.03.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 2012;5:ra20. doi: 10.1126/scisignal.2002521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Cosson P, Letourneur F. Coatomer interaction with di-lysine endoplasmic reticulum retention motifs. Science. 1994;263:1629–1631. doi: 10.1126/science.8128252. [DOI] [PubMed] [Google Scholar]
- 18.Ma W, Goldberg J. Rules for the recognition of dilysine retrieval motifs by coatomer. EMBO J. 2013;32:926–937. doi: 10.1038/emboj.2013.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Emmer, B. T. et al. The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9. Elife7, e38839 (2018). [DOI] [PMC free article] [PubMed]
- 20.Mitrovic S, Ben-Tekaya H, Koegler E, Gruenberg J, Hauri HP. The cargo receptors Surf4, endoplasmic reticulum-Golgi intermediate compartment (ERGIC)-53, and p25 are required to maintain the architecture of ERGIC and Golgi. Mol. Biol. Cell. 2008;19:1976–1990. doi: 10.1091/mbc.e07-10-0989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hansen AL, et al. Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling. Proc. Natl Acad. Sci. USA. 2018;115:E7768–E7775. doi: 10.1073/pnas.1806239115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lippincott-Schwartz J, et al. Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell. 1990;60:821–836. doi: 10.1016/0092-8674(90)90096-W. [DOI] [PubMed] [Google Scholar]
- 23.Haag SM, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018;559:269–273. doi: 10.1038/s41586-018-0287-8. [DOI] [PubMed] [Google Scholar]
- 24.Jeremiah N, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Invest. 2014;124:5516–5520. doi: 10.1172/JCI79100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014;371:507–518. doi: 10.1056/NEJMoa1312625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Melki I, et al. Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. J. Allergy Clin. Immunol. 2017;140:543–552. doi: 10.1016/j.jaci.2016.10.031. [DOI] [PubMed] [Google Scholar]
- 27.Deng Z, et al. A defect in thymic tolerance causes T cell-mediated autoimmunity in a murine model of COPA syndrome. J. Immunol. 2020;204:2360–2373. doi: 10.4049/jimmunol.2000028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Deng Z, et al. A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome. J. Exp. Med. 2020;217:e20201045. doi: 10.1084/jem.20201045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Katoh Y, Nozaki S, Hartanto D, Miyano R, Nakayama K. Architectures of multisubunit complexes revealed by a visible immunoprecipitation assay using fluorescent fusion proteins. J. Cell Sci. 2015;128:2351–2362. doi: 10.1242/jcs.168740. [DOI] [PubMed] [Google Scholar]
- 30.Uemura T, et al. A cluster of thin tubular structures mediates transformation of the endoplasmic reticulum to autophagic isolation membrane. Mol. Cell. Biol. 2014;34:1695–1706. doi: 10.1128/MCB.01327-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The authors declare that the data supporting the findings of this study are available within the paper, Supplementary Information or from the corresponding author upon request. Source data are provided with this paper.